Business Context and Reporting Period
Lifemd, Inc. (LFMD) is a direct-to-patient telehealth company operating two primary segments: Telehealth (including brands LifeMD, RexMD, and ShapiroMD) and WorkSimpli (a SaaS document platform). This Form 10-Q covers the quarterly period ended March 31, 2025. The company reported its first net income in the period, driven by significant revenue growth in its telehealth division.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $65.70 million | $44.14 million |
| Gross Profit | $57.05 million | $39.54 million |
| Gross Margin | 86.8% | 89.6% |
| Operating Income | $2.54 million | ($6.17 million) loss |
| Net Income | $1.92 million | ($6.65 million) loss |
| Net Income (Common Stockholders) | $0.61 million | ($7.54 million) loss |
| EPS (Diluted) | $0.01 | ($0.19) |
| Cash from Operations | $3.07 million | $5.20 million |
| Cash Balance (End of Period) | $34.39 million | $35.11 million |
| Total Debt (Current + Long-term) | $18.43 million | $18.33 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 49% year-over-year, primarily driven by a 70% surge in Telehealth revenue ($52.46M vs. $30.84M). WorkSimpli revenue remained flat at approximately $13.24M.
- Profitability Turnaround: The company shifted from an operating loss of $6.17M in Q1 2024 to an operating income of $2.54M in Q1 2025. This was achieved despite a 21% increase in selling and marketing expenses ($29.19M) to drive customer acquisition.
- Expense Increases: Total operating expenses rose 19% to $54.51M. Notable increases included customer service expenses (up 66% due to headcount growth) and general and administrative expenses (up 11%).
- Cash Flow: Net cash provided by operating activities decreased to $3.07M from $5.20M, largely due to a reduction in deferred revenue growth and decreases in accounts payable and accrued expenses compared to the prior year.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects to maintain positive operating cash flows for the next 12 months. As of May 5, 2025, cash on hand was approximately $24.5 million. The company has $53.3 million available under an At-The-Market (ATM) sales agreement.
- Debt Obligations: The company has a $40 million convertible senior secured credit facility (Avenue Facility) with $19 million outstanding as of March 31, 2025. The facility matures on October 1, 2026, with interest rates at 12.5%.
- Strategic Initiatives: The company expanded insurance acceptance to Medicare beneficiaries in April 2025 and integrated with LillyDirect for Zepbound access. A new wholly-owned pharmacy in Lancaster, PA, is operational.
- Subsequent Events: On April 25, 2025, the company acquired assets from OHHMD, PLLC (a women's health provider) for stock consideration, including an earn-out structure based on patient and revenue milestones.
- Risks and Controls: The company disclosed that its internal controls over financial reporting were not effective due to material weaknesses in IT general controls and business process controls. While remediation steps were taken in 2024, the effectiveness of these controls has not yet been fully tested.
Investor Verification Checklist
- Sustainability of Margins: Verify if the 86.8% gross margin is sustainable given the 16% cost of revenue increase in the telehealth segment.
- Internal Control Remediation: Monitor the timeline for the remediation of material weaknesses in internal controls to ensure future financial reporting reliability.
- Debt Covenants: Confirm continued compliance with the Avenue Facility covenants, specifically the requirement to maintain $5 million in unrestricted cash and $2 million in trailing six-month cash flow.
- Customer Acquisition Costs: Assess the efficiency of the increased marketing spend ($29.2M) relative to the growth in active patient subscribers (approx. 291,000).
- Insurance Expansion: Track the rollout of Medicare and private insurance acceptance to validate the projected revenue growth from these channels.